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Abstract 
Background: Considerable success in reducing malaria incidence and mortality has been achieved in Brazil, lead-
ing to discussions over the possibility of moving towards elimination. However, more than reporting and counting 
clinical cases, elimination will require the use of efficient tools and strategies for measuring transmission dynamics 
and detecting the infectious reservoir as the primary indicators of interest for surveillance and evaluation. Because 
acquisition and maintenance of anti-malarial antibodies depend on parasite exposure, seroprevalence rates could be 
used as a reliable tool for assessing malaria endemicity and an adjunct measure for monitoring transmission in a rapid 
and cost-effective manner.
Methods: This systematic review synthesizes the existing literature on seroprevalence of malaria in the Brazilian 
Amazon Basin. Different study designs (cross-sectional surveys and longitudinal studies) with reported serological 
results in well-defined Brazilian populations were considered. Medline (via PubMed), EMBASE and LILACS databases 
were screened and the articles were included per established selection criteria. Data extraction was performed by two 
authors and a modified critical appraisal tool was applied to assess the quality and completeness of cross-sectional 
studies regarding defined variables of interest.
Results: From 220 single records identified, 23 studies were included in this systematic review for the qualitative 
synthesis. Five studies reported serology results on Plasmodium falciparum, 14 papers assessed Plasmodium vivax and 
four articles reported results on both Plasmodium species. Considerable heterogeneity among the evaluated malarial 
antigens, including sporozoite and blood stage antigens, was observed. The majority of recent studies analysed IgG 
responses against P. vivax antigens reflecting the species distribution pattern in Brazil over the last decades. Most of 
the published papers were cross-sectional surveys (73.9%) and only six cohort studies were included in this review. 
Three studies pointed to an association between antibodies against circumsporozoite protein of both P. falciparum 
and P. vivax and malaria exposure. Furthermore, five out 13 cross-sectional studies evidenced a positive association 
between IgG antibodies to the conserved 19-kDa C-terminal region of the merozoite surface protein 1 of P. vivax 
(PvMSP119) and malaria exposure.
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Background
Recent emphasis and constant efforts on malaria elimi-
nation and eradication goals are changing the global 
malaria epidemiology scenario. Indeed, there has been 
an extraordinary scale-up of malaria control interven-
tions over the last decade, which resulted in a substan-
tial decline in global malaria morbidity and mortality [1]. 
In this perspective, the Americas have made substantial 
progress in reducing malaria cases. Indeed, 18 of the 21 
countries in the region are now classified as being in the 
pre-elimination and elimination phases. On the other 
hand, four countries accounted for 83% of cases reported 
in the Americas in 2015: Venezuela (30%), Brazil (24%), 
Peru (19%), and Colombia (10%) [1]. Despite the con-
siderable number of cases which still requires attention 
(143,000 cases in 2015), Brazil achieved a significant 
decrease in malaria incidence over the last 15 years [2]. 
Nowadays, an optimistic approach highlights mainly 
Plasmodium falciparum elimination targets, the species 
responsible for <15% of all malaria cases diagnosed in the 
Brazilian Amazon Basin.
Because past and current malaria control policies and 
implementation strategies have successfully reduced 
transmission in Brazil, the measurement of malaria-asso-
ciated morbidity may become increasingly difficult which 
may undermine elimination efforts. Moreover, it is worth 
noting that surveillance methods based solely on detec-
tion of symptomatic clinical illness are unlikely to provide 
accurate estimates of ongoing transmission in the Brazil-
ian Amazon Basin [2–4]. Under these circumstances, 
monitoring malaria transmission is pivotal for estimating 
disease burden, planning control strategies and evaluat-
ing the impact of malaria control interventions. Indeed, 
surveillance systems can help programme managers to 
reduce malaria transmission by providing information 
on the populations in which incidence of malaria is high-
est and, therefore, to whom resources should be targeted. 
They also provide information on changes in incidence 
over time that require attention [5, 6]. However, there is 
no consensus about which methods are more refined and 
adequate to monitor changes in transmission intensity to 
support malaria control programmes.
Malaria infection imposes an antibody ‘footprint’ that 
will last longer than the infection itself. Anti-malarial 
antibody responses reflect cumulative malaria expo-
sure in a population and may be considered an alter-
native tool to measure malaria transmission intensity 
as well as to evaluate changes in exposure [7]. Previous 
studies have shown that serological prevalence with 
age-stratified sampling allowing for calculation of sero-
conversion rates is an important adjunct measure for 
monitoring transmission and to provide key informa-
tion for control programmes on malaria transmission 
patterns, especially when parasite rates are low [8–10]. 
In contrast to the lifespan of the vector or the half-
life of discrete infections, antibodies persist markedly 
longer than individual malaria infections or infected 
mosquitoes, which suggests that seroprevalence rates 
could provide a reliable tool for assessing malaria ende-
micity [11].
There have been several studies investigating antibody 
responses against different malaria antigens in Brazil. 
However, there is a great dissimilarity between them, 
which may prevent a conclusive analysis to establish a 
comprehensive panorama of malaria epidemiology over 
the past decades in Brazil. Therefore, the overall aim 
of this study is to collate data from relevant serological 
surveys of anti-malarial antibodies conducted in Brazil 
through a systematic review strategy. Specific objectives 
of this study include: (a) the description of representative 
studies on seroprevalence of antibodies against P. vivax 
and P. falciparum in Brazil; (b) list antigenic-used targets 
according to their usability; and, (c) identify knowledge 
gaps for malaria serological research in Brazil.
Methods
Search strategy
The search comprised different studies designs (cross-
sectional surveys and longitudinal studies) with reported 
serological results (seropositivity proportions and anti-
body levels) in well-defined populations. Papers included 
in this review were searched using Medline (via Pub-
Med), EMBASE and LILACS (Latin America and Car-
ibbean Health Sciences Literature) databases published 
up until 25 May 2016. The search was conducted using 
the following search terms: ‘Malaria AND (vivax OR fal-
ciparum) AND (serology OR antibody OR antibody OR 
immunoglobulin) AND Brazil’.
Conclusions: This systematic review identifies potential biomarkers of P. falciparum and P. vivax exposure in areas 
with variable and unstable malaria transmission in Brazil. However, this study highlights the need for standardization 
of further studies to provide an ideal monitoring tool to evaluate trends in malaria transmission and the effectiveness 
of malaria intervention programmes in Brazil. Moreover, the score-based weighted tool developed and used in this 
study still requires further validation.
Keywords: Plasmodium falciparum, Plasmodium vivax, Antibodies, Brazil, Sero-epidemiology, Systematic review
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Inclusion criteria
This systematic literature review included studies report-
ing data from serological surveys of antibodies against 
malarial antigenic targets (whole parasites, recombinant 
and synthetic peptides) in addition to the following inclu-
sion criteria: (1) studies must have provided a description 
of markers and laboratory methods used for the surveys; 
(2) data on the population age structure and geographi-
cal location characteristics must have been reported; and, 
(3) description of sample strategy and/or study design 
should have been reported. Studies that measured total 
IgG, total IgM or IgG sub-classes humoral immune 
responses were considered. This review included articles 
written in both English and Portuguese.
Exclusion criteria
This review excluded case reports, experimental studies in 
animal models, studies based solely on blood bank volun-
teers, pregnant women, and any other particular groups 
that were not considered to be representative of the gen-
eral population of interest. Studies were also excluded if 
the recruitment of individuals was based on their clinical 
status (all malaria-positive individuals) or if only IgG sub-
classes (IgG1, IgG2, IgG3, IgG4) were analysed. Reports with 
insufficient data, literature reviews and studies from non-
endemic areas (imported cases or outbreaks outside the 
Brazilian Amazon endemic area) have also been excluded.
Data extraction
Two independent review authors used the inclusion 
and exclusion criteria to identify possible studies based 
on titles and abstracts. Relevant information from the 
selected articles was extracted and entered into a stand-
ardized Excel datasheet by the same two authors inde-
pendently. Any differences were resolved on further 
discussion with a third author before including the data 
in the review. Data were extracted using a pre-defined 
form, which included the following information: publica-
tion data (journal, authors, period of study, year of pub-
lication); demographic and ecological characteristics of 
the study site (rural vs urban, transmission variation due 
to seasonality); study design and sampling procedures, 
serological markers and methods used for measurement; 
parasite diagnostic methods used [microscopy or poly-
merase chain reaction (PCR)]; study population charac-
teristics (age distribution and gender); seroprevalence 
(overall and antigen specific); parasite prevalence and 
transmission intensity in the study site (annual parasite 
index or yearly incidence).
Critical appraisal
Most of the validated tools or checklists to appraise the 
quality of cross-sectional studies have been designed 
to assess randomized interventional studies. In 1998, 
Downs and Black [12] proposed a checklist to assess the 
methodological quality of randomized and non-rand-
omized studies of health care interventions, which has 
been used in a number of systematic reviews since then. 
The Newcastle-Ottawa Scale (NOS) was developed to 
assess the quality of non-randomized studies (case–con-
trol and cohort) and has also been used recently as a 
quality assessment tool in systematic reviews and meta-
analysis [13]. Despite these two existing checklists for 
non-randomized studies, none of them was designed to 
assess cross-sectional research as they mainly focus on 
cohort and case–control studies. A new weighted tool 
was developed based on these modified checklists pro-
posed by Downs and Black and the NOS (see Table  1). 
Articles were assessed against a score-based system, 
which combined elements of both these scales, giving 
weight to studies whose samples were truly representa-
tive of the population. Papers with a score >70% were 
included in this review (minimum nine out of 12 possi-
ble points for cross-sectional and ten out of 14 possible 
points for cohort studies).
Results
Identification and general description of included studies
The search strategy yielded 413 papers across the three 
different databases used (Medline, EMBASE, LILACS). 
After removing duplicated papers, 220 articles were 
screened. Based on their titles and abstracts, 171 non-rel-
evant papers were excluded and 49 full-text articles were 
assessed for eligibility. Six of these papers were excluded 
based on the inclusion and exclusion criteria (lacked rel-
evant information on the variables of interest: ascertain-
ment of malaria diagnosis, description of the serological 
method used, target population and representativeness of 
general population). Twenty articles scored <70% when 
the critical appraisal tool was applied and were therefore 
excluded. Hence, 23 studies were included in this review 
for the qualitative synthesis of the published papers 
(Fig. 1).
The studies were published between 1975 and 2016, 
with a larger proportion of these after the year 2000. 
Only five studies were published in the 1990s and a single 
one in 1975. Details of the 23 articles included in this sys-
tematic review are shown in Table 2.
The majority of studies (14 out 23) used microscopic 
observations of thick blood smears to determine malaria 
infection, whereas others used PCR in addition to 
microscopy.
The studies selected were conducted among popu-
lations living in six different states within the Brazil-
ian Amazon Basin (Rondônia, Amazonas, Acre, Pará, 
Mato Grosso, Roraima). Most of them analysed humoral 
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immune responses among distinct populations living in 
Rondônia State. Two different studies were conducted 
among indigenous populations. One of them took place 
in four isolated indigenous tribes from the Amazon 
region [14] and the other one in Roraima among the 
Yanomami Amerindians [15].
Five studies reported serology results on P. falciparum, 
14 papers assessed P. vivax and four articles reported 
results on both Plasmodium species. The majority of 
published papers were cross-sectional surveys (82.6%) 
and only four cohort studies were included in this review.
Enzyme-linked immunosorbent assay (ELISA) alone or 
in combination with other methods, was the chosen sero-
logical assay used in 21 (91.3%) of the included papers. 
Indirect fluorescent antibody test (IFAT) was used in five 
studies published between 1975 and 2004. Furthermore, 
a considerable number of P. falciparum and P. vivax 
antigens were used to determine IgG-specific antibody 
responses among different populations in the Brazilian 
Amazon endemic region (Table 2).
The 23 retrieved sero-epidemiological studies inves-
tigated the IgG immune responses to several malaria 
vaccine candidates. The majority of them included 
recombinant proteins, which represent the merozo-
ite surface proteins (MSPs) of both P. vivax and P. fal-
ciparum. Other recombinant antigens have also been 
included, such as CS, AMA1 and DBP as well as P. 
falciparum and P. vivax blood stages crude extract 
(Table 2).
It is worth noting that among the 23 selected studies, 
eight also examined IgG subclasses responses to malarial 
antigens. Only four studies examined the profile of IgM 
responses in parallel to IgG antibodies against P. falcipa-
rum whole parasites antigens [15–17] or against recom-
binant variant-specific PvMSP1 antigens [18].
Studies on seroprevalence reflect changes in temporal 
malaria distribution in the Brazilian Amazon Basin
The species-specific antigens used in the eligible studies 
were consistent with the case distribution data for P. fal-
ciparum and P. vivax reported by the Brazilian Ministry 
of Health since 1960. The first paper on malaria sero-epi-
demiology included in this review was published in 1975 
by Jeffery et al. [19] representing pioneer work in Brazil, 
pointing out the usefulness of a serological method for 
the characterization of malaria endemicity. This repeated 
cross-sectional survey studied 4270 individuals, males 
and females and both children and adults living in seven 
different communities in Mato Grosso State (MT) and 
six communities in what is nowadays known as the Mato 
Grosso do Sul State (MS). The authors sampled mem-
bers of urban and rural communities from April 1970 
to September 1971 to account for variations in malaria 
transmission patterns at the rainy or dry seasons. At that 
Table 1 Critical appraisal tool used at this review
Cross-sectional studies score a maximum of 12 points. Cohort studies score a maximum of 14 points
Critical appraisal tool
1. Was the research question or objective in this paper clearly stated? (1 point)
2. The study clearly describes exposures and outcomes (1 point)
3. The study clearly describes basic characteristics of participants (1 point)
4. The results were adjusted for possible confounding variables through stratification or multivariate analysis (1 point)
5. Statistical test
    i. The statistical test used to analyse the data is clearly described and appropriate, and the measurement of the association is presented, including 
confidence intervals and probability level (1 point)
    ii. The statistical test is not appropriate, not described or incomplete
6. The study informs the loss to follow-up characteristics: numbers and reasons (1 point—cohort studies only)
7. Participants were followed for the same time or the study was adjusted for different follow-up times (1 point—cohort studies only)
8. The measures used for the main outcomes were accurate: description of the technique for the diagnosis of malaria and antibody measurement (1 point)
9. The demographic characteristics were comparable or adjusted: age and geographic area (1 point)
10. The participants of different groups were recruited in the same period of time (1 point)
11. Representativeness of the sample:
    i. Truly representative of the average in the target population: all subjects or random sampling (2 points)
    ii. Somewhat representative of the average in the target population: non-random sampling (1 point)
    iii. Selected group of users
12. Sample size:
    i. Justified and satisfactory (1 point)
    ii. Not justified
13. Ascertainment of the exposure (risk factor)
    i. Validated measurement tool or non-validated measurement tool, but the tool is available or described (1 point)
    ii. No description of the measurement tool
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time, similar proportions of P. falciparum and P. vivax 
confirmed cases were diagnosed in the Brazilian endemic 
region. The authors ascertained malarial infection by 
thick blood smears and applied IFAT based on sera eluted 
from paper filter in populations where constant move-
ment of people and variations in transmission intensity 
made the collection of reliable malariometric informa-
tion particularly difficult. The overall seroprevalence 
(both P. falciparum and P. vivax) varied from 4.3 to 13.6% 
with a prevalence of malaria infection ranging from 0.8 
to 2.3% across four surveys. Stratified seroprevalence per 
age group is reported only for the Cuiaba region (MT), 
where 2.9–7.4% of children aged 5–14 years had positive 
antibodies against P. falciparum or P. vivax. Of note is the 
fact that based on such extremely low parasite rates and 
relatively low IFAT positivity, the large-scale insecticide-
spraying programme in Mato Grosso State was inter-
rupted during the 1970s.
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Fig. 1 Flow chart with a summary of the articles included in this systematic review. Titles and abstracts were screened from 220 papers. Of these, 
171 non-relevant articles were excluded because reported data on imported cases in non-endemic areas included febrile patients attending health-
care facilities, serologically tested convalescent individuals, reported non-human experimental data, were case-reports or presented any other 
exclusion criteria identifiable in their abstracts. A further six papers were found to be ineligible after reading the 49 full-text articles assessed for 
eligibility criteria (lacked relevant information on the variables of interest: ascertainment of malaria diagnosis, description of the serological method 
used, target population and representativeness of general population). Of the 49 potentially eligible papers, 20 were considered to be of poor qual-
ity (scored <70% when the critical appraisal tool was applied) and were therefore excluded
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Table 2 Summary of seroprevalence studies included in the systematic review by year of publication
Identification  
(references)
Year of  
publication
State Study design Sample 
sizea
Target antigenbc Overall  
seroprevalence (%)
95% CI
Rodrigues da Silva et al. 
[34]
2016 Rondônia Cross-sectional 545 PvMSP9-RIRII 58 53.86–62.14
PvMSP9-E795/A808 32.5 28.57–36.43
Sanchez-Arcila et al. [30] 2015 Rondônia Cross-sectional 279 PvMSP119 66 60.44–71.56
PvAMA-1(Picchia pastoris) 63 57.33–68.67
Cunha et al. [28] 2014 Pará Cross-sectional 1330 PfMSP119 25.6 23.25–27.95
PfAMA-1 12.7 10.91–14.49
PvMSP119 36.3 33.72–38.88
PvAMA-1 32.5 29.98–35.02
Ferreira et al. [38] 2014 Rondônia Cross-sectional 253 PvRMC-RBP1 47.1 40.95–53.25
PvRBP1-23-751 60 53.96–66.04
Versiani et al. [41] 2013 Amazonas Cohort 308 PvMSP1 (N-terminus) 35.4 30.06–40.74
Lima Junior et al. [33] 2012 Rondônia Cross-sectional 276 PvMSP119 86.7 82.69–90.71
PvMSP3-alpha 77 72.04–81.96
PvMSP9 76 70.96–81.04
Kano et al. [29] 2012 Amazonas Cross-sectional 432 PvDBP 49.5 44.79–54.21
PvMSP119 86.7 83.5–89.9
Lima Junior et al. [32] 2011 Rondônia Cross-sectional 282 PvMSP3-alpha 78 73.17–82.83
Souza-Silva et al. [40] 2010 Acre Cohort 366 PvDBP 18.6 14.61–22.59
Lima Junior et al. [31] 2008 Rondônia Cross-sectional 306 PvMSP9 74 69.1–78.91
Ladeia-Andrade et al. 
[27]
2007 Amazonas Cross-sectional 812
778
PvMSP119 66.3
d 62.93–69.43
PfMSP119 (Saccharomyces 
cerevisae)
53.5d 49.96–56.95
Bastos et al. [18] 2007 Acre Cohort 376 PvMSP119 54.3 46.29–59.34
Suarez-Mutis et al. [24] 2007 Amazonas Cross-sectional 98 PvMSP119 46.9 37.02–56.78
Scopel et al. [25] 2007 Acre Cohort 356 PfMSP-2 S20 28.1 23.43–32.77
PfMSP-2 FC27 22.2 17.88–26.52
PfMSP-2 AM89 7.3 4.6–10
PfMSP-2 3D7 6.2 3.69–8.71
PfMSP-2 FUP/CP 6.2 3.69–8.71
Nogueira et al. [39] 2006 Rondônia Cohort 429 N-terminus–PvMSP1 35d 30.6–39.59
PvMSP119 41.5
d 36.93–46.21
Tran et al. [37] 2005 Rondônia Cross-sectional 294 PvDBP 67 61.63–72,37
PvRBP-1 66 60.59–71.47
Marcano et al. [15] 2004 Roraima Cross-sectional 101 Pf blood stages (IFAT) 72.1 63.35–80.85
Alexandre et al. [26] 1997 Amazonas Cross-sectional 241 PfR44 26.5e 20.93–32.07
PfAg-T 57.7e 51.43–63.91
Arruda et al. [14] 1996 Pará Cross-sectional 430 PfCS 44f 39.33–48.71
Pf blood stage (IFAT) 68f 63.54–72.36
PvCS 60.1e 55.42–64.68
Pv blood stage (IFAT) 73.2e 68.98–77.36
Ferreira et al. [17] 1994 Rondônia Cohort 50 Pf Exoantigens 30g 17.3–42.7
Pf Somatic Antigens 40g 26.42–53.58
Oliveira-Ferreira et al. 
[16]
1992 Rondônia Cross-sectional 1617 PfCS (Immunoradio-
metric)
5.9 4.75–7.05
Pf Blood stage (IFAT) 49.2 46.76–51.64
Kremsner et al. [23] 1992 Acre Cross-sectional 645 PvCS 17.3f 14.33–20.17
PvCS (VK247) 4.8f 3.11–6.39
Page 7 of 15Folegatti et al. Malar J  (2017) 16:107 
During the 1980s, malaria cases increased in the Bra-
zilian Amazon region as an effect of environmental and 
demographic changes during the military dictatorship 
regime [2, 20, 21]. Despite that decade being considered 
crucial in shaping the new malaria epidemiological sce-
nario in the Brazilian Amazon region, none of the sero-
epidemiological studies published in the 1980s could be 
selected for this systematic review. There was one poten-
tial study conducted in 1982 among the 49 full-text arti-
cles assessed for eligibility written by Ferraroni et al. [22]. 
However, this survey did not provide enough information 
regarding infection rates among the studied population 
and was excluded from the review.
The five selected works carried out during the 1990s fol-
lowed the malaria distribution trend in the late 1980s when 
similar number of malaria cases due to P. falciparum and P. 
vivax were registered in the Brazilian Basin. Indeed, two 
out of five of those studies, which were conducted in Acre 
and Pará States, used P. falciparum and P. vivax total pro-
teins as target antigens to detect specific antibodies among 
endemic populations [14, 23]. Two studies used P. falcipa-
rum blood-stage antigens as well the repeated epitopes of 
circumsporozoite protein [14, 16].
The majority of papers published during the 2000s 
focused on P. vivax antigens (MSP1, MSP3, MSP9, AMA1, 
RBP1, DBP) (Table 2) reflecting this species predominance 
in the Brazilian endemic regions after implementation of 
the Programme for the Intensification of Malaria Control 
in October 1999 and the National Programme for Malaria 
Prevention and Control in 2005. In fact, only three studies 
aiming to evaluate the antibody responses to P. falciparum 
antigens were conducted during the 2000s [15, 24, 25].
Antibody responses to Plasmodium falciparum 
and Plasmodium vivax CS antigens and their association 
with malaria exposure
Few cross-sectional studies aimed to characterize the 
antibody responses against (CS) proteins of P. falciparum 
and P. vivax. The three selected studies were conducted 
during the 1980s in three different states (Acre, Ron-
dônia, Pará) depicting low transmission rates (parasite 
prevalence <10%) [14, 16, 23]. Interestingly, these hetero-
geneous studies revealed an association between anti-CS 
antibodies and age as detailed below. The first study used 
synthetic peptides representing the repeat region of the 
CS proteins for P. vivax (classic and VK247 variant) and P. 
falciparum [23]. Two surveys were conducted in the state 
of Acre involving 645 individuals living in two differ-
ent communities (about 10% of total population). Acute 
malaria infection varied from 1.2 to 5.3% for P. vivax and 
from 0.625 to 3.3% to P falciparum at the surveyed com-
munities. While the seroprevalence of anti-CS targeting 
classic P. vivax varied from 9 to 25%, the VK247 variant 
was less frequently observed varying from 1.2 to 10% 
among sampled subjects. The prevalence of antibodies to 
both P. falciparum and P. vivax CS proteins was higher 
in areas of recent migration mainly in 1987. Furthermore, 
an overall decline in the seroprevalence of anti-CS anti-
bodies in 1990 compared to 1987 was reported and may 
reflect a significant decrease in the number of malaria 
cases reported by the Brazilian Ministry of Health at that 
time as a consequence of DDT spraying. Moreover, anti-
bodies against CS proteins of both P. falciparum and P. 
vivax increased with age (p < 0.001) in the 1987 and 1990 
surveys. Taken together, these results point out an asso-
ciation between anti-sporozoite antibodies and malaria 
exposure.
A similar association was described in a study compris-
ing five cross-sectional surveys between 1986 and 1989 
in four different communities in Rondônia State [16]. A 
total of 1617 people were included in this study, which 
assessed anti-P. falciparum CS antibodies. A seropreva-
lence of 6% was revealed but no relationship observed 
between the frequency of anti-sporozoites (CS) and 
gender, time of residence or malaria infection. How-
ever, a significantly higher frequency was observed in 
Table 2 continued
Identification  
(references)
Year of  
publication
State Study design Sample 
sizea
Target antigenbc Overall  
seroprevalence (%)
95% CI
Jeffery et al. [19] 1975 Mato Grosso Cross-sectional 4270 Pf and Pv blood stage 
(IFAT)
10.5h 9.58–11.42
a Sample size refers to number of participants for whom serology was determined
b If other serological methods were used instead ELISA, it is shown in parenthesis
c If other expression systems were used to produce recombinant antigens instead E.coli in fusion with histydine tag (His6) or Glutationa S-transferase (GST), it is 
shown in parenthesis
d Combined cross-sectional surveys
e Average seroprevalence in all age groups
f Average seroprevalence for all cross-sectional surveys
g Results shown for the last survey conducted
h Average prevalence for both antigens (P. falciparum and P. vivax blood stages) across four surveys
Page 8 of 15Folegatti et al. Malar J  (2017) 16:107 
individuals over 30 years old (p < 0.001) and in those with 
a history of more than nine previous malaria episodes 
(p < 0.001).
In agreement with the two previous published papers, 
data collected from cross-sectional surveys conducted 
between 1986 and 1988 among four indigenous Bra-
zilian tribes in Pará State (n =  430 natives) revealed an 
increased anti-sporozoite seropositivity according to age 
for both P. vivax and P. falciparum [14].
Cross‑sectional studies related to Plasmodium falciparum 
blood‑stage antigens
Six cross-sectional studies evaluated the IgG profiles to 
total P. falciparum asexual blood-stage antigens [14–16, 
19, 24, 26] in inhabitants of different localities within 
the Brazilian Amazon. The areas studied are considered 
hypo/meso-endemic with variable and unstable malaria 
transmission. Two different techniques, IFAT and ELISA, 
were used to measure anti-total blood stage IgG across 
the populations studied. The relationship between sero-
prevalence and cumulative exposure to malaria was het-
erogeneous among the studies: some studies evidenced 
an increase in seroprevalence with age [19, 24, 26] while 
others suggested no association between the proportion 
of responders and age of sampled subjects [14–16].
Recombinant antigens of P. falciparum were also used 
in cross-sectional studies aiming to define the patterns 
of naturally occurring antibodies in different epidemio-
logical settings within the Amazon Basin [26–28]. Such 
studies used recombinant proteins representing three 
different antigens, which have been considered poten-
tial antigen candidates for vaccines against falciparum 
malaria: the 72  kDa heat-shock protein from P. falcipa-
rum (Pf72/Hsp70-1), the 19  kDa fragment of PfMSP-1 
that remains on the surface of merozoite during invasion 
(PfMSP-119) and the apical membrane antigen 1 of 3D7 
strain (PfAMA1).
A cross-sectional survey conducted in Candeias do 
Jamari (Rondônia State), a small town in a hypo-endemic 
area with unstable malaria transmission, selected 241 
non-immune migrants using household-based rand-
omization criteria [26]. Blood stage antibodies against 
the Pf72/Hsp 70-1 protein were measured by ELISA and 
stratified by age group. Both prevalence and levels of spe-
cific antibodies were associated with age and time of resi-
dence in an endemic area. Only 6.6% of participants had 
a positive blood film for malaria and they were all symp-
tomatic (56% of these due to P. falciparum).
Two different studies measured naturally acquired IgG 
antibodies to the conserved 19-kDa C-terminal region of 
the merozoite surface protein 1- PfMSP-119. Two cross-
sectional surveys enrolling 594 individuals (both children 
and adults) living in riverine communities along the Jau 
and Unini rivers (Amazonas State) evidenced a sero-
prevalence around 52%, which was positively correlated 
with age (OR 1.04 95% CI 1.019–1.06 p  <  0.0001) [27]. 
Another sero-epidemiological study enrolled 1330 inhab-
itants of six different municipalities in Para State (urban, 
rural, migrant, native populations) between 2006 and 
2010 [28]. Despite the low parasite prevalence at those 
six localities (ranging from 0 to 5%), a considerable over-
all serological response to PfMSP-119 antigen (25.6%) was 
reported. This latter study also evaluated the humoral 
immune response to the apical membrane antigen 1 
(AMA1) of P. falciparum. An overall prevalence of 12.7% 
was detected, probably reflecting the little contribution 
of P. falciparum to the malaria burden at the different 
localities studied during the years of 2006–2010.
Cross‑sectional studies and antibody responses 
to Plasmodium vivax antigens
A total of 13 cross-sectional studies investigated humoral 
responses to P. vivax antigens. Among them, two works 
reported IgG responses to total P. vivax asexual blood 
stage antigens measured by IFAT [14, 19]. As already 
mentioned above in relation to P. falciparum, the rela-
tionship between seroprevalence and age was contrast-
ing, based on data from those two papers.
Most sero-epidemiological studies in the Brazil-
ian Amazon Basin has been focused on the PvMSP-119 
antigen. Among 13 cross-sectional studies, five were 
conducted aiming to measure the naturally acquired anti-
bodies to such conserved fragment of P. vivax merozo-
ite. Different papers have reported a positive association 
between anti-PvMSP-119 antibodies and malaria expo-
sure as detailed below.
Suarez-Mutis et  al. [24] sampled 98 individuals over 
2  years, living in five small riverine communities near 
Barcelos (Amazonas State). The study was designed to 
evaluate the continuous malaria transmission in the area 
and the possible role played by asymptomatic carriers. 
Only 1.02% of inhabitants had a malaria-positive blood 
film but 20.4% cases of P. vivax infection were detected 
by PCR. A seroprevalence of 46.9% for PvMSP-119 was 
reported and the probability of a positive IgG specific 
response was 3.44 times higher in individuals older than 
15 years in comparison to those younger. Similar results 
were described by Ladeia-Andrade et al. [27] across two 
sectional surveys conducted among 594 endemic resi-
dents (both children and adults) from riverine commu-
nities along the Jau and Unini rivers (Amazonas State). 
Anti-PvMSP-119 was positive in 69.6%, half way through 
the rainy season, and 64.0% at the middle of the dry sea-
son. Age was positively correlated with seropositivity (OR 
1.04 95% CI 1.019–1.06 p  <  0.0001). Furthermore, very 
strong evidence for an association between the number 
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of previous malaria episodes and anti-PvMSP-119 anti-
bodies was observed among 432 subjects living in Rio 
Pardo, Amazonas State, in a cross-sectional study con-
ducted in 2008 [29].
A recent study demonstrated that serology could be 
used to measure and monitor transmission of malaria in 
the Brazilian Amazon endemic region [28]. The authors 
determined the antibody levels and seroconversion rates 
to P. vivax merozoite antigens (PvMSP-119 and PvAMA1) 
in individuals living in areas of varying P. vivax endemic-
ity in Pará State. Seroprevalence for any P. vivax anti-
gens ranged from 19.6% (low transmission) to 77.5% 
(high transmission) corroborating the official Brazilian 
annual parasite index (API). However, low parasite preva-
lence (0–5%) was detected in participants from those six 
localities.
Data on antibodies to PvMSP-119 and PvAMA1 was 
also extracted from a paper published by Sanchez-Arcila 
et al. [30] that evaluated the influence of intestinal para-
sites in P. vivax-specific responses. A total of 279 people 
(14–43 years old) from a rural settlement were included. 
Overall seroprevalence was 74% for any antigen, 66% 
for PvMSP-119 and 63% for PvAMA-1. Interestingly, 
responses to both PvAMA1 and PvMSP-119 were lower 
in individuals with intestinal parasites.
Other MSPs antigens have also been evaluated among 
Amazonian populations. Three papers included in this 
review used different target antigens for assessing sero-
prevalence of P. vivax in communities in Rondônia State, 
enrolling both migrant and native populations. The first 
paper published in 2008 [31] analysed 306 samples using 
the PvMSP-9 antigen (variants RIRII, RII and NT). An 
overall seroprevalence of 74% was found with 13% of 
blood films being positive for malaria. A positive cor-
relation between years of residence in the area and IgG 
antibody reactivity index was found for all variants in 
both communities (highest p value =  0.02). The second 
paper by the same group [32] used PvMSP-3 variants 
as the target antigen in 282 samples. An overall sero-
prevalence of 78% (for any positive variant) was found 
with a 12% prevalence of infection. Seropositivity cor-
related positively with years of residence in an endemic 
area (p < 0.05) and was also associated with the number 
of previous malaria episodes. The third published paper 
[33] sampled 276 individuals and the target antigens 
used were PvMSP119, PvMSP3-α and PvMSP-9. The fre-
quency of responders shows that IgG antibody reactivity 
to PvMSP-119 was 86.7% and the frequency of positive 
individuals for at least one of the recombinant proteins 
representing PvMSP-3a and PvMSP-9 sequences was 77 
and 76%, respectively. Another paper conducted at those 
same localities in Rondônia State verified 58% of positive 
antibody responses to recombinant PvMSP9-RIRII and 
32.5% to PvMSP9 E795-A808 protein [34]. In agreement 
to previous studies, seropositive individuals for PvMSP9-
RIRII had a higher median of years of residence in the 
endemic area.
The vivax Duffy binding protein (PvDBP), a leading 
malaria vaccine candidate that plays a critical role in P. 
vivax erythrocyte invasion [35, 36], has been used in two 
different sero-epidemiological studies. Tran et  al. [37] 
assessed the seroprevalence of naturally acquired PvDBP-
RII in three communities in the state of Rondônia. Native 
and migrant populations were evaluated in this paper, 
which included 294 individuals (children and adults). An 
overall seroprevalence of 67% was found for anti-PvDBP. 
The prevalence of acute malaria infection varied from 8 
to 37% across the three communities. The authors found 
weak evidence for an association between seropositivity 
and increasing age and time of residence in the endemic 
area (OR 2.25 and 95% CI 0.79–6.43). Evidence was 
stronger for individuals living in the endemic area for 
more than 30 years (OR 3.3 and 95% CI 1.17–9.35) and 
a higher number of previous malaria episodes. Individu-
als with more than 15 previous malaria episodes had 6.98 
times the odds of being anti-PvDBP positive (95% CI 
1.79–27.17) than individuals with no previous malaria 
episodes. The PvDBP was also evaluated in a well-con-
solidated agricultural settlement of the Brazilian Ama-
zon region [29] showing similar results. The frequency 
of antibodies against PvDBPII–IV was 49.5% and age 
was the only predictor significantly associated with the 
presence of anti-PvDBP antibodies (adjusted OR 1.05, 
95% CI 1.02–1.08, p = 0.005). Each additional year of age 
increased the probability of having anti-PvDBP antibod-
ies by 5%.
Reticulocyte binding protein 1 (PvRBP1), another pro-
tein involved in the reticulocyte-specificity of P. vivax 
blood-stage infections was investigated in two published 
papers. The first paper measures specific IgG antibod-
ies to five recombinant fragments spanning the length of 
the extracellular domain of PvRBP1 [37]. Seroprevalence 
for any of the five PvRBP1 fragments was 66%. Positive 
IgG responses were correlated to the level of malaria 
exposure (past infections and years of residence in the 
endemic area) after adjustment for age. Recently, Ferreira 
and collaborators [38] used a chimeric synthetic peptide 
and the non-chimeric recombinant reticulocyte binding 
protein to assess the seroprevalence in a cross-sectional 
study, which included 253 samples. Total IgG responses 
were observed in 47.1% of the population to the chimeric 
PvRMC-RBP1 and in 60% to the non-chimeric protein 
PvRBP123-751. There was a significant difference in the 
response to these two recombinant proteins (p = 0.0031). 
Past malaria infections and time of residence in endemic 
area were associated with higher levels of IgG against 
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both antigens. No association was found between sero-
positivity and time since last malaria episode.
Cohort studies
Only six cohort studies were included in this systematic 
review. These longitudinal studies focused on different 
antigens of P. falciparum [17, 25] and P. vivax [18, 39–
41]. A crucial point to be mentioned here is that these six 
published papers used different periods of follow-up after 
parasite detection to determine asymptomatic infections.
Regarding P. falciparum, two studies were conducted 
in two distinct epidemiological settings. The first cohort 
study included in this review was published in 1994 by 
Ferreira and collaborators [17]. The authors followed 50 
individuals aged one-51  years for 1  year between 1991 
and 1992. Participants lived in a rural settlement (total 
population of 180) in Urupá, Rondônia State, a hypo-
endemic area for malaria at that time. Most of the par-
ticipants were migrants from non-endemic areas of the 
country. An outbreak took place during follow-up with 
48 malaria attacks (28 due to P. falciparum) among 25 
individuals. Seroprevalence for P. falciparum somatic and 
exo-antigens increased after the outbreak. An increase 
from 13 to 30% IgG positivity for exo-antigens and from 
20 to 40% for somatic antigens was reported. No associa-
tion between previous malaria immunity and the profile 
of malaria response could be drawn from this study.
The other cohort study analysed the prevalence of 
antibodies recognizing variant antigens representing the 
MSP-2 of P. falciparum (FC27 and 3D7 dimorphic allelic 
families) among 356 individuals living in a rural com-
munity in Acre State [25]. Seropositivity for five MSP-2 
variant antigens ranged from 6.2 to 28.1%, the S20 vari-
ant being the most recognized. Evidence for a correla-
tion between the level of IgG antibodies and age and time 
of residence in the Amazon was observed. Cumulative 
malaria exposure or the presence of variant-specific anti-
bodies matching the MSP-2 type in infecting parasites 
were not considered major predictors of clinical severity.
With regard to P. vivax, it is worth mentioning that 
combined results from two studies showed an evidence 
of association of PvMSP1 N-terminal responses and 
time of residence in the Brazilian endemic regions [39, 
41]. Nogueira et al. [39] conducted three cross-sectional 
surveys between September 1998 and September 1999 
among 180 individuals living in a riverine community 
in Rondônia State. A positive association between time 
of residence in the endemic area and seropositivity was 
found for individuals living in the community for more 
than 15 years (OR 30.35 95% CI 2.42–381 for individuals 
living in the community for more than 30 years). A small 
cohort was followed up for 1 year and a hazard risk for 
acquiring malaria of 2.95 (95% CI 1.14–7.65) for individ-
uals with negative serology (N-terminus PvMSP-1) was 
described.
A second paper from the same research group analysed 
the profile of antibodies against the N-terminal region 
of the PvMSP-1 in a 1-year follow-up conducted among 
308 individuals living in a rural community in Amazonas 
State [41]. Seropositivity of 35.4% for the target antigen 
and 14% parasite infection prevalence were reported. Age 
was associated with seropositivity (OR 1.02 95% CI 1.01–
1.03, p = 0.002; a 2% increase for each additional year in 
age). This study also analysed the relationship between 
asymptomatic infection and the presence of such spe-
cific antibodies. Individuals with asymptomatic malaria 
(detected by PCR only) had an OR of positive antibody 
of 2.45 (95% CI 1.06–5.69, p  =  0.036) compared with 
malaria negative individuals. A Kaplan–Meier time to 
event analysis was performed with 293 participants. The 
total IgG anti-MSP1 (N-terminus) was detected to be an 
important protective factor against vivax malaria clinical 
attacks (p = 0.029).
Another cohort study included in this review was 
published by Bastos et  al. [18] in 2007. People liv-
ing in a small community in Acre were followed up for 
15  months where 376 subjects were considered eligible 
for the serological study. Over 60% of the study popula-
tion were migrants. Variants of PvMSP1 were used as 
target antigen and 54.3% had a positive serology (ELISA) 
for PvMSP119. The authors found a positive correlation 
(p < 0.005) between IgG PvMSP-1 antibodies and time of 
residence in the Amazon.
The prevalence of anti-DBP antibodies was investi-
gated in 366 people living in Ramal do Granada (Acre 
State) [40]. Two cross-sectional surveys were conducted 
but only the baseline data are analysed in this review. 
Anti-DBP antibodies were present in 18.6% of individu-
als. Time (years) of residence in the Amazon region was 
associated with the presence of IgG antibodies (OR 1.02 
95% CI 1.0–1.04 representing a 2% increase in the odds 
of having a positive anti-DBP antibody for every 1-year 
increase in residence). Age, past or current malaria infec-
tion were not considered strong predictors of antibody 
positivity.
Discussion
This systematic literature review included 23 studies 
reporting malaria seroprevalence data in the Brazilian 
Amazon endemic region. Most of the studies (60.87%) 
reported data on P. vivax exclusively, reflecting the epi-
demiological changes in Plasmodium species distribu-
tion in Brazil. Malaria cases shifted from predominantly 
caused by P. falciparum in the 1960s to P. vivax, the 
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latter now being responsible for over 80% of cases in 
the country. Studies included in this review were highly 
heterogeneous and reported seroprevalence varied with 
the transmission risk in the area, target antigen used and 
target population (migrant, indigenous, native or mixed 
communities).
Since the Global Malaria Eradication Programme pro-
posed by the WHO in 1955, serology has been used to 
measure malaria exposure and was a prominent method 
in early elimination attempts reported in papers pub-
lished in the 1970s [19, 42–44]. As these elimination 
attempts were abandoned, the use of serological char-
acterization was discouraged and was no longer found 
on subsequent publications. With little use over several 
decades, these serologic assays lacked standardized, 
reproducible and objective methods [42, 45]. Recent 
technological improvements mean that serology has now 
become a much more robust tool for transmission meas-
urement, but there is still a need to standardize ELISA 
protocols and antigens [11]. This scenario is reflected in 
this systematic review, which highlights the significantly 
more frequent use of serological methods in malaria 
over the past decades, as depicted from the progressively 
increasing number of papers published since 1975.
The Brazilian Amazon region is characterized by highly 
variable and unstable malaria transmission. The risk of 
acquiring malaria varies substantially even within the 
same state. These different transmission patterns could 
explain some of the variation in seroprevalence found 
in the selected studies, in addition to the sensitivity of 
the chosen target antigen. Twelve different antigens 
were used in P. vivax studies and another ten different 
targets in P. falciparum studies. Thus, a gross seroprev-
alence comparison across these communities with vari-
able malaria transmission using several different targets 
would be inappropriate.
It is important to note that studies involving native 
indigenous populations are under-represented. Only two 
papers [14, 15] evaluated indigenous communities in 
Pará and Rondônia States. However, genetic indigenous 
backgrounds, epidemiological settings, period of evalua-
tion, and antigens tested were markedly distinct between 
the studies preventing any comparative analysis. There 
are currently no updated malaria sero-epidemiological 
surveys among the indigenous communities in the Brazil-
ian Amazon. A better understanding of malaria transmis-
sion in these vulnerable communities is urgently needed. 
Indeed, the first National Survey of Indigenous People’s 
Health and Nutrition in Brazil conducted between 2008 
and 2009 gives insufficient information on malaria diag-
nosis and outcomes among indigenous children and 
women [46].
Target antigens and association with malaria exposure
There seems to be suggestive evidence that higher titres 
of IgG antibodies against some antigen targets (but 
not all) correlate with the number of years living in the 
endemic area and not necessarily with age. Sero-epide-
miological studies conducted in Africa have shown an 
association with the presence of malaria antibodies and 
age, which has been used as surrogate marker for malaria 
exposure [47, 48]. Here it is worth considering the par-
ticular epidemiological scenario of malaria in the Brazil-
ian Amazon Basin. In the late 1960s, a Brazilian national 
demographic policy stimulated migration from the non-
endemic southern areas towards the Amazon in order 
to increase population density in the underpopulated 
northern areas of the country. These previous migration 
policies translate into a higher proportion of migrant 
population with less long-term exposure to malaria liv-
ing in the communities assessed by the studies reported 
here. Thus, a clear correlation between age and malaria 
exposure was not expected in the majority of the selected 
sero-epidemiological studies, especially those conducted 
during the 1990s. However, even for studies enrolling 
inhabitants from stable communities, such as agricultural 
settlements and riverine populations, there was not a 
strong association between age and the profile of specific 
antibody responses. Living in the endemic area for more 
than ten to 15  years seems to be better correlated with 
seropositivity for malaria antigens based on the selected 
studies.
Three selected heterogeneous studies conducted dur-
ing the 1980s [14, 16, 23] evidenced an association 
between anti-CS antibodies and age and therefore seem 
to reflect the cumulative exposure to malaria-infected 
mosquitoes. Interestingly, the antibodies against syn-
thetic peptides containing the tandem repeated immuno-
dominant epitope of P. vivax [16] and P. falciparum [16, 
23] CS proteins were associated to age even in migrant 
populations with limited exposure to malaria. Similar 
association between sporozoite-specific antibodies and 
stratified age was found in indigenous tribes [23]. Con-
sidering that studies enrolling the CS proteins have not 
been carried out since the early 1990s in endemic Brazil-
ian populations, an interpretation of the potential use of 
specific antibodies as a biomarker of malaria exposure 
should be cautiously analysed.
Few studies attempted to investigate the associa-
tion between seropositivity and months since the last 
malaria episode. However, the cross-sectional design 
adopted by most of the authors is subject to recall bias 
from individuals surveyed. The criteria used to ascertain 
previous malaria infections is not clearly defined in any 
of the reported cross-sectional studies, apart from the 
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paper assessing PvCS and PfCS antigens where positivity 
against these targets was clearly associated with individu-
als reporting around ten previous malaria episodes [16].
The 19  kDa conserved fragment of MSP-1 from both 
P. falciparum and P. vivax has been considered a poten-
tial marker for protection against malaria as well as a 
surrogate marker for malaria exposure in geographi-
cally diverse populations [49, 50]. This systematic review 
corroborates those findings describing an association 
between PvMSP-119/PfMSP-119 and malaria exposure 
parameters (age, time of residence in endemic areas, and 
number of previous malaria episodes) in cross-sectional 
sero-epidemiological studies [24, 27–29]. Although the 
gene sequences of MSP-119 antigens are exclusive to each 
Plasmodium species, considerable homology has been 
reported among them [51] and, therefore, cross-reactiv-
ity in co-endemic areas could be expected. However, a 
recent study demonstrated that IgG antibodies to recom-
binant MSP-119 antigens of the four major human malaria 
parasites are species-specific in Zimbabwean populations 
[52]. Here none of the selected studies assessed the inter-
species cross-reactivity of MSP-119 serological responses, 
an issue that remains to be established among Brazilian 
Amazonian populations.
It has been suggested that serological methods might 
be used to distinguish between relapse and new P. vivax 
infections by measuring exposure to mosquito saliva 
through detection of anti-saliva antibodies or through 
the measurement of hypnozoite-specific signals [42]. 
However, none of the studies included in review identi-
fied target antigens or described differences in antibody 
levels in relation to relapses or new infections. Relapse 
infections were not distinguished from new infections in 
any of the reported studies. One important point to be 
addressed is the latest sequencing data suggesting that 
P. vivax has a more variable and diverse genome than P. 
falciparum. Thus, multi-antigenic approaches such as 
micro-array would allow more detailed screening of the 
different antigen variants that could possibly be used to 
distinguish relapses from new infections [53, 54].
Immunity and asymptomatic infection
Antibodies are important mediators of naturally acquired 
immunity (NAI) that controls blood-stage parasitae-
mia, thereby reducing clinical symptoms and life-threat-
ening complications. The role of specific antibodies is 
evidenced by experimental animal models and, most 
importantly, classical passive transfer studies in which 
antibodies from malaria immune adults were success-
fully used to treat children with severe malaria [55, 56]. 
Moreover, several studies have evidenced the role of 
antibodies in NAI, involving protection from infection 
and severe clinical symptoms. NAI has been extensively 
demonstrated for P. falciparum, and more recently for P. 
vivax, in regions of high and low transmission [57]. Inter-
estingly, NAI is acquired more rapidly in P. vivax infec-
tion compared to P. falciparum, which may be due to the 
differing biological features related to the two species, 
such as the ability of P. vivax to maintain hypnozoites in 
the liver. Thus, a differential contribution of antibodies to 
NAI in P. vivax and P. falciparum infections is expected. 
Brazilian malaria distribution since the early 1960s and 
the fluctuations in proportions of slide-confirmed P. fal-
ciparum and P. vivax infections diagnosed over the last 
decades represent an ideal scenario to address this puz-
zling question. Notwithstanding, little is known about 
NAI in areas of less intense malaria transmission in the 
Amazon Basin mainly due to few cohort studies being 
conducted in the region.
Asymptomatic malaria has been a subject of increasing 
interest in the Brazilian context but is still lacking sub-
stantial data. Serology has the potential to detect not only 
ongoing blood-stage infections missed by conventional 
microscopy, but also recent infections, either sympto-
matic or not. Despite this potential, the use of serol-
ogy for targeting asymptomatic carriers has been rarely 
reported in Brazil and the available data do not provide 
conclusive or comparative results.
Sensitive diagnostic methods, such as PCR, and an 
appropriate follow-up period are required to identify 
asymptomatic malaria infection. Certainly, these req-
uisites impose substantial costs on epidemiological 
surveys, which may explain the scarce number of lon-
gitudinal sero-epidemiological studies in Brazil. From 
all the studies that attempted to investigate the associa-
tion between seropositivity and asymptomatic infection, 
two cohort studies suggested that PvMSP-1  N-terminal 
region might be a target for protective immunity [39, 41]. 
These longitudinal studies used clearly defined criteria 
to establish the occurrence of asymptomatic infection 
among well-defined populations in Rondônia and Ama-
zonas States. In fact, these studies prospectively assessed 
the relationship between seropositivity and time elapsed 
until next malaria episode and found a protective asso-
ciation for PvMSP-1 N-terminus after a 1-year follow-up. 
However, such association requires further investigation 
in other epidemiological settings to validate the N-ter-
minal of PvMSP-1 as a putative protective biomarker in 
endemic populations.
Conclusions
Although serology has been recognized as a valid sur-
veillance tool, the vast majority of studies in this review 
used it as the means to identify potential targets for the 
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development of a vaccine against the disease. Major 
issues with the representativeness of the sample arise 
from this approach, as most of the authors used a con-
venient sampling method instead of structured sample 
size calculations and random selection of individuals. 
Despite the bias introduced by the sampling methods 
used and the focus on identifiable targets for a candidate 
vaccine, valuable malaria transmission information can 
still be retrieved from these studies.
The review also highlights the need for longitudinal 
studies to better understand the role of these antibodies 
in malaria protection and asymptomatic P. vivax infec-
tions. There is a gap in research to be filled by better 
designed, cross-sectional, epidemiological surveys with 
improved sampling procedures. Surveys focusing on the 
broader epidemiological and sero-surveillance aspects of 
malaria seroprevalence are needed, considering the aim 
of most published studies included in this review was to 
identify prospective malaria vaccine candidates.
This systematic review reveals that IgG antibodies 
against two parasite proteins, the CS and the MSP119 
proteins, of both P falciparum and P. vivax, may be con-
sidered as putative biomarkers of malaria exposure in 
areas with variable and unstable malaria transmission in 
the Brazilian Amazon. However, standardization of tar-
get antigens and their relationship with malaria exposure 
are issues that require extra attention and need to be 
addressed before seroprevalence methods can be incor-
porated as a surveillance tool into the Brazilian malaria 
programme. A useful biomarker to differentiate relapses 
from new P. vivax infections is yet to be explored by 
further research. Furthermore, the proposed critical-
appraisal, score-based, weighted tool developed and used 
in this study to assess cross-sectional studies still requires 
further validation.
In conclusion, efforts will need to be made to ensure 
greater consistence among further sero-epidemiolog-
ical studies in the Brazilian Amazon endemic region to 
improve the ability to compare different results that 
should contribute to understanding malaria transmission.
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